董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rebecca Robertson | 女 | Chairman of the Board | 64 | 未披露 | 未持股 | 2025-11-07 |
| Myoungil Cha | 男 | Director | 48 | 未披露 | 未持股 | 2025-11-07 |
| Peyton Howell | 女 | Director | 58 | 未披露 | 未持股 | 2025-11-07 |
| Joao Malagueira | 男 | Director | 59 | 未披露 | 未持股 | 2025-11-07 |
| Kathleen McGroddy Goetz | 女 | Director | 61 | 未披露 | 未持股 | 2025-11-07 |
| John Sheridan | 男 | Director,President and Chief Executive Officer | 69 | 未披露 | 未持股 | 2025-11-07 |
| Rajwant Sodhi | 男 | Director | 51 | 未披露 | 未持股 | 2025-11-07 |
| Christopher Twomey | 男 | Director | 65 | 未披露 | 未持股 | 2025-11-07 |
| Sandra Beaver | 女 | Independent Director | 48 | 未披露 | 未持股 | 2025-11-07 |
| Christopher J. Twomey | 男 | Director | 65 | 15.43万美元 | 未持股 | 2025-11-07 |
| John F. Sheridan | 男 | Director,President and Chief Executive Officer | 70 | 91.03万美元 | 未持股 | 2025-11-07 |
| Sandra Beaver | 女 | Independent Director | 47 | 未披露 | 未持股 | 2025-11-07 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elizabeth A. Gasser | 女 | Executive Vice President and Chief Strategy and Product Officer | 49 | 未披露 | 未持股 | 2025-11-07 |
| Leigh A. Vosseller | 女 | Executive Vice President, Chief Financial Officer and Treasurer | 52 | 未披露 | 未持股 | 2025-11-07 |
| John Sheridan | 男 | Director,President and Chief Executive Officer | 69 | 未披露 | 未持股 | 2025-11-07 |
| Rick Carpenter | 男 | Chief Technical Officer | 62 | 未披露 | 未持股 | 2025-11-07 |
| Shannon Hansen | 女 | Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary | 59 | 未披露 | 未持股 | 2025-11-07 |
| Jean Claude Kyrillos | 男 | Executive Vice President, Chief Operating Officer | 61 | 未披露 | 未持股 | 2025-11-07 |
| Mark Novara | 男 | Executive Vice President and Chief Commercial Officer | 50 | 未披露 | 未持股 | 2025-11-07 |
| Leigh Vosseller | 女 | Executive Vice President, Chief Financial Officer and Treasurer | 52 | 未披露 | 未持股 | 2025-11-07 |
| Rick Carpenter | 男 | Chief Technical Officer | 62 | 未披露 | 未持股 | 2025-11-07 |
| John F. Sheridan | 男 | Director,President and Chief Executive Officer | 70 | 91.03万美元 | 未持股 | 2025-11-07 |
| Susan M. Morrison | 女 | Executive Vice President and Chief Administrative Officer | 46 | 316.53万美元 | 未持股 | 2025-11-07 |
董事简历
中英对照 |  中文 |  英文- Rebecca Robertson
-
Rebecca Robertson,是Versant Ventures的创始人和普通合伙人,自1999年以来,她专门从事医疗设备和诊断领域的投资。此外,通过Longridge Business Advisors,她自2017年4月起提供商业咨询服务和董事会服务。在加入Versant之前,她曾在Chiron Corporation的一个部门Chiron Diagnostics担任高级副总裁,除了领导该部门的业务发展工作外,她还负责重症监护业务部门。在加入Chiron之前,Robertson女士是消费品公司EGIS的联合创始人兼副总裁,并曾在强生公司Lifescan担任运营和财务方面的高级管理职务。Robertson女士拥有康奈尔大学化学工程学士学位。
Rebecca Robertson,is a founder and General Partner at Versant Ventures where she has specialized in investing in the areas of medical devices and diagnostics since 1999. In addition, through Longridge Business Advisors, she has provided business advisory services and board services since April 2017. Prior to Versant, she served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the critical care business unit in addition to leading the division's business development efforts. Prior to joining Chiron, Ms. Robertson was a co-founder and Vice President at Egis, a consumer products company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. Ms. Robertson holds a B.S. in Chemical Engineering from Cornell University. - Rebecca Robertson,是Versant Ventures的创始人和普通合伙人,自1999年以来,她专门从事医疗设备和诊断领域的投资。此外,通过Longridge Business Advisors,她自2017年4月起提供商业咨询服务和董事会服务。在加入Versant之前,她曾在Chiron Corporation的一个部门Chiron Diagnostics担任高级副总裁,除了领导该部门的业务发展工作外,她还负责重症监护业务部门。在加入Chiron之前,Robertson女士是消费品公司EGIS的联合创始人兼副总裁,并曾在强生公司Lifescan担任运营和财务方面的高级管理职务。Robertson女士拥有康奈尔大学化学工程学士学位。
- Rebecca Robertson,is a founder and General Partner at Versant Ventures where she has specialized in investing in the areas of medical devices and diagnostics since 1999. In addition, through Longridge Business Advisors, she has provided business advisory services and board services since April 2017. Prior to Versant, she served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the critical care business unit in addition to leading the division's business development efforts. Prior to joining Chiron, Ms. Robertson was a co-founder and Vice President at Egis, a consumer products company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. Ms. Robertson holds a B.S. in Chemical Engineering from Cornell University.
- Myoungil Cha
-
Myoungil Cha,拥有20多年横跨医疗保健价值链的全球经验。查先生目前在Verily担任首席产品官,领导产品开发。在2024年3月加入Verily之前,他曾于2021年6月至2024年2月担任Carbon Health的总裁兼首席战略官。他于2015年8月至2021年5月担任苹果健康战略计划负责人,负责开发和领导产品计划和全球战略合作伙伴关系。在其职业生涯的早期,查先生是西海岸战略和企业融资业务的负责人和联合负责人,也是麦肯锡公司医疗保健投资者业务的联合负责人。查先生拥有哈佛法学院的京东、哈佛商学院的MBA学位和哈佛学院的生化科学AB学位。
Myoungil Cha,has more than 20 years of global experience across the healthcare value chain. Mr. Cha currently serves as Chief Product Officer at Verily where he leads product development. Prior to joining Verily in March 2024, he served as President and Chief Strategy Officer at Carbon Health from June 2021 to February 2024. He served as Head of Health Strategic Initiatives at Apple from August 2015 to May 2021 where he developed and led product initiatives and global strategic partnerships. Earlier in his career, Mr. Cha was a Principal and Co-Leader of the West Coast Strategy and Corporate Finance Practice as well as Co-Leader of the Healthcare Investor Practice at McKinsey & Company. Mr. Cha holds a JD from Harvard Law School, an MBA from Harvard Business School and an AB in Biochemical Sciences from Harvard College. - Myoungil Cha,拥有20多年横跨医疗保健价值链的全球经验。查先生目前在Verily担任首席产品官,领导产品开发。在2024年3月加入Verily之前,他曾于2021年6月至2024年2月担任Carbon Health的总裁兼首席战略官。他于2015年8月至2021年5月担任苹果健康战略计划负责人,负责开发和领导产品计划和全球战略合作伙伴关系。在其职业生涯的早期,查先生是西海岸战略和企业融资业务的负责人和联合负责人,也是麦肯锡公司医疗保健投资者业务的联合负责人。查先生拥有哈佛法学院的京东、哈佛商学院的MBA学位和哈佛学院的生化科学AB学位。
- Myoungil Cha,has more than 20 years of global experience across the healthcare value chain. Mr. Cha currently serves as Chief Product Officer at Verily where he leads product development. Prior to joining Verily in March 2024, he served as President and Chief Strategy Officer at Carbon Health from June 2021 to February 2024. He served as Head of Health Strategic Initiatives at Apple from August 2015 to May 2021 where he developed and led product initiatives and global strategic partnerships. Earlier in his career, Mr. Cha was a Principal and Co-Leader of the West Coast Strategy and Corporate Finance Practice as well as Co-Leader of the Healthcare Investor Practice at McKinsey & Company. Mr. Cha holds a JD from Harvard Law School, an MBA from Harvard Business School and an AB in Biochemical Sciences from Harvard College.
- Peyton Howell
-
Peyton Howell于2024年5月被任命为Parexel的首席执行官,Parexel是一家服务于生命科学行业的全球领先的临床研究机构,同时也是该公司的董事会成员。她此前自2022年9月起担任Parexel的首席运营和增长官,自2018年5月起担任其首席商务和战略官。在加入Parexel之前,Howell女士的经历包括在财富20强公司AmerisourceBergen(现为Cencora)担任高级领导职务,最近担任卫生系统和专业护理解决方案总裁。在AmerisourceBergen之前,Howell女士是Lash Group的创始人,在被AmerisourceBergen收购后担任了近10年的总裁。
Peyton Howell,was appointed Chief Executive Officer of Parexel, a leading global clinical research organization servicing the life sciences industry, in May 2024 and also serves on the company's Board of Directors. She previously served as Parexel's Chief Operating and Growth Officer since September 2022, and as its Chief Commercial and Strategy Officer since May 2018. Prior to joining Parexel, Ms. Howell's experience includes senior leadership positions with AmerisourceBergen (now Cencora), a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions. Prior to AmerisourceBergen, Ms. Howell was a founder of Lash Group and served as President for nearly 10 years following its acquisition by AmerisourceBergen. - Peyton Howell于2024年5月被任命为Parexel的首席执行官,Parexel是一家服务于生命科学行业的全球领先的临床研究机构,同时也是该公司的董事会成员。她此前自2022年9月起担任Parexel的首席运营和增长官,自2018年5月起担任其首席商务和战略官。在加入Parexel之前,Howell女士的经历包括在财富20强公司AmerisourceBergen(现为Cencora)担任高级领导职务,最近担任卫生系统和专业护理解决方案总裁。在AmerisourceBergen之前,Howell女士是Lash Group的创始人,在被AmerisourceBergen收购后担任了近10年的总裁。
- Peyton Howell,was appointed Chief Executive Officer of Parexel, a leading global clinical research organization servicing the life sciences industry, in May 2024 and also serves on the company's Board of Directors. She previously served as Parexel's Chief Operating and Growth Officer since September 2022, and as its Chief Commercial and Strategy Officer since May 2018. Prior to joining Parexel, Ms. Howell's experience includes senior leadership positions with AmerisourceBergen (now Cencora), a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions. Prior to AmerisourceBergen, Ms. Howell was a founder of Lash Group and served as President for nearly 10 years following its acquisition by AmerisourceBergen.
- Joao Malagueira
-
Joao Malagueira,为全球企业带来了超过25年的糖尿病、医疗设备和诊断解决方案业务经验。Malagueira先生目前担任Hologic三个部门的总裁,负责欧洲、中东和非洲的整个投资组合。在2023年10月开始担任这一职务之前,他自2019年1月起担任Hologic三个部门的EMEA国际副总裁,并于2015年6月至2018年12月担任Hologic诊断解决方案部门的EMEA和加拿大国际副总裁。他在欧洲、非洲、独联体和中东的上市模式和战略方面拥有丰富的经验和证明的成功。在加入Hologic之前,Malagueira先生在强生工作了超过15年,在整个欧洲、中东和非洲地区担任商业领导职务,在那里他领导了糖尿病解决方案业务LifeScan和Animas的成功转型和市场份额增长。Malagueira先生拥有Catolica Lisbon商业和经济学院的MBA和市场营销高级学位。他拥有里斯本大学药物科学和临床分析硕士学位。
Joao Malagueira,brings more than 25 years of experience in diabetes, medical devices and diagnostics solutions businesses with global corporations. Mr. Malagueira is currently President for three divisions at Hologic and responsible for the entire portfolio in the EMEA. Prior to starting this role in October 2023, he served as International Vice President, EMEA for three divisions at Hologic, since January 2019, and as International Vice President, EMEA and Canada, for the Hologic Diagnostics Solutions division, from June 2015 to December 2018. He possesses extensive experience and proven success of go-to-market models and strategies in Europe, Africa, CIS, and the Middle East. Prior to Hologic, Mr. Malagueira enjoyed more than 15 years at Johnson & Johnson, in commercial leading roles across EMEA, where he led successful turnarounds and market share growth of the diabetes solutions businesses, LifeScan and Animas. Mr. Malagueira holds an MBA and an Advanced Degree in Marketing from Catolica Lisbon School of Business and Economics. He holds a MS in Pharmaceutical Sciences and Clinical Analysis from University of Lisbon. - Joao Malagueira,为全球企业带来了超过25年的糖尿病、医疗设备和诊断解决方案业务经验。Malagueira先生目前担任Hologic三个部门的总裁,负责欧洲、中东和非洲的整个投资组合。在2023年10月开始担任这一职务之前,他自2019年1月起担任Hologic三个部门的EMEA国际副总裁,并于2015年6月至2018年12月担任Hologic诊断解决方案部门的EMEA和加拿大国际副总裁。他在欧洲、非洲、独联体和中东的上市模式和战略方面拥有丰富的经验和证明的成功。在加入Hologic之前,Malagueira先生在强生工作了超过15年,在整个欧洲、中东和非洲地区担任商业领导职务,在那里他领导了糖尿病解决方案业务LifeScan和Animas的成功转型和市场份额增长。Malagueira先生拥有Catolica Lisbon商业和经济学院的MBA和市场营销高级学位。他拥有里斯本大学药物科学和临床分析硕士学位。
- Joao Malagueira,brings more than 25 years of experience in diabetes, medical devices and diagnostics solutions businesses with global corporations. Mr. Malagueira is currently President for three divisions at Hologic and responsible for the entire portfolio in the EMEA. Prior to starting this role in October 2023, he served as International Vice President, EMEA for three divisions at Hologic, since January 2019, and as International Vice President, EMEA and Canada, for the Hologic Diagnostics Solutions division, from June 2015 to December 2018. He possesses extensive experience and proven success of go-to-market models and strategies in Europe, Africa, CIS, and the Middle East. Prior to Hologic, Mr. Malagueira enjoyed more than 15 years at Johnson & Johnson, in commercial leading roles across EMEA, where he led successful turnarounds and market share growth of the diabetes solutions businesses, LifeScan and Animas. Mr. Malagueira holds an MBA and an Advanced Degree in Marketing from Catolica Lisbon School of Business and Economics. He holds a MS in Pharmaceutical Sciences and Clinical Analysis from University of Lisbon.
- Kathleen McGroddy Goetz
-
Kathleen McGroddy Goetz,拥有超过25年的经验,在业务发展、战略、研发和产品管理方面领导全球团队。她将从微电子到云、高级数据分析、人工智能、硬件、软件和中间件的开创性技术商业化,重点是医疗保健和生命科学应用。从2018年10月到2021年6月,McGroddy-Goetz博士在达索系统公司旗下的深思信息服务担任战略合作伙伴关系全球主管,她还在该公司兼任其他战略、联盟和营销主管职务。此前,她于1992年开始在IBM担任过多个领导职务,最近的一次职务是丨沃森健康战略与创新部门副总裁。她担任圣心大学医疗保健信息学和行政管理的兼职教授,以及Ridefield Rides的董事会主席,Ridefield是一家致力于确保老年人和行动不便的人保持生活质量的非营利组织。McGroddy-Goetz博士拥有SUNY宾厄姆顿大学的物理学学士学位和康奈尔大学的分子生物物理学博士学位。
Kathleen McGroddy Goetz,has more than 25 years of experience leading global teams across business development, strategy, research and development, and product management. She has commercialized pioneering technologies spanning from microelectronics through cloud, advanced data analytics, artificial intelligence, hardware, software, and middleware with an emphasis on healthcare and life sciences applications. From October 2018 through June 2021, Dr. McGroddy-Goetz served as the Global Head of Strategic Partnerships at Medidata Solutions, a Dassault Systemès Company, where she also concurrently held other strategy, alliances and marketing executive roles. Previously, she held various leadership positions at IBM beginning in 1992, and most recently was Vice President, Strategy and Innovation, IBM Watson Health. She serves as an adjunct professor of healthcare informatics and administration at Sacred Heart University, and as board chair for Rides for Ridgefield, a non-profit organization dedicated to ensuring seniors and those with mobility disabilities maintain quality of life. Dr. McGroddy-Goetz holds a B.S. in Physics from SUNY Binghamton and a Ph.D. in Molecular Biophysics from Cornell University. - Kathleen McGroddy Goetz,拥有超过25年的经验,在业务发展、战略、研发和产品管理方面领导全球团队。她将从微电子到云、高级数据分析、人工智能、硬件、软件和中间件的开创性技术商业化,重点是医疗保健和生命科学应用。从2018年10月到2021年6月,McGroddy-Goetz博士在达索系统公司旗下的深思信息服务担任战略合作伙伴关系全球主管,她还在该公司兼任其他战略、联盟和营销主管职务。此前,她于1992年开始在IBM担任过多个领导职务,最近的一次职务是丨沃森健康战略与创新部门副总裁。她担任圣心大学医疗保健信息学和行政管理的兼职教授,以及Ridefield Rides的董事会主席,Ridefield是一家致力于确保老年人和行动不便的人保持生活质量的非营利组织。McGroddy-Goetz博士拥有SUNY宾厄姆顿大学的物理学学士学位和康奈尔大学的分子生物物理学博士学位。
- Kathleen McGroddy Goetz,has more than 25 years of experience leading global teams across business development, strategy, research and development, and product management. She has commercialized pioneering technologies spanning from microelectronics through cloud, advanced data analytics, artificial intelligence, hardware, software, and middleware with an emphasis on healthcare and life sciences applications. From October 2018 through June 2021, Dr. McGroddy-Goetz served as the Global Head of Strategic Partnerships at Medidata Solutions, a Dassault Systemès Company, where she also concurrently held other strategy, alliances and marketing executive roles. Previously, she held various leadership positions at IBM beginning in 1992, and most recently was Vice President, Strategy and Innovation, IBM Watson Health. She serves as an adjunct professor of healthcare informatics and administration at Sacred Heart University, and as board chair for Rides for Ridgefield, a non-profit organization dedicated to ensuring seniors and those with mobility disabilities maintain quality of life. Dr. McGroddy-Goetz holds a B.S. in Physics from SUNY Binghamton and a Ph.D. in Molecular Biophysics from Cornell University.
- John Sheridan
-
John Sheridan,2012年3月至2013年2月担任安全设备和系统提供商Rapiscan Systems,Inc.的首席运营官。Sheridan先生于2004年11月至2010年3月期间担任医疗技术公司Volcano医疗器械的研发和运营执行副总裁。从2002年5月到2004年5月,Sheridan先生在医疗技术公司CardioNet公司担任运营执行副总裁,该公司现以BioTelemetry,Inc.(纳斯达克:BEAT)的名义运营。1998年3月至2002年5月,在医学影像公司Digirad Corporation担任运营副总裁。Sheridan先生此前曾于2021年3月至2025年4月期间担任Acutus Medical, Inc.(纳斯达克:AFIB)的董事。Sheridan先生拥有西佛罗里达大学化学学士学位和波士顿大学MBA学位。
John Sheridan,served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan previously served as a director of Acutus Medical, Inc. (Nasdaq: AFIB) from March 2021 to April 2025. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University. - John Sheridan,2012年3月至2013年2月担任安全设备和系统提供商Rapiscan Systems,Inc.的首席运营官。Sheridan先生于2004年11月至2010年3月期间担任医疗技术公司Volcano医疗器械的研发和运营执行副总裁。从2002年5月到2004年5月,Sheridan先生在医疗技术公司CardioNet公司担任运营执行副总裁,该公司现以BioTelemetry,Inc.(纳斯达克:BEAT)的名义运营。1998年3月至2002年5月,在医学影像公司Digirad Corporation担任运营副总裁。Sheridan先生此前曾于2021年3月至2025年4月期间担任Acutus Medical, Inc.(纳斯达克:AFIB)的董事。Sheridan先生拥有西佛罗里达大学化学学士学位和波士顿大学MBA学位。
- John Sheridan,served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan previously served as a director of Acutus Medical, Inc. (Nasdaq: AFIB) from March 2021 to April 2025. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University.
- Rajwant Sodhi
-
Rajwant Sodhi,在全球信息学、软件服务技术和电子商务业务解决方案方面拥有超过25年的经验,横跨医疗保健、金融和电信行业。此前,他曾于2017年7月至2021年8月担任ResMed软件即服务(SaaS)业务总裁,在此之前,他担任Healthcare Informatics(HI)总裁,领导ResMed HI解决方案的开发,并将ResMed提升至目前作为全球数字健康领导者的地位,拥有不断扩大的基于设备和SaaS的产品组合。他于2012年通过收购Umbian Inc.加入ResMed,他是该公司的联合创始人兼总裁。在ResMed和Umbian之前,Sodhi先生曾在金融服务行业工作,设计、开发和管理SaaS解决方案。他曾于2005年至2009年担任Skipjack Financial Services的业务发展高级副总裁兼首席技术官,并于2000年至2005年担任TransActive Ecommerce Solutions的联合创始人兼首席技术官。Sodhi先生是Forefront Dermatology、EyeCare Partners和NovaResp Technologies的董事会成员。Sodhi先生拥有新斯科舍省哈利法克斯Dalhousie大学的MBA和数学与统计学学士学位。
Rajwant Sodhi,has more than 25 years of experience in global informatics, software service technology and ecommerce business solutions, across the healthcare, financial, and telecom industries. Previously he served as the President of ResMed's software as a service (SaaS) business from July 2017 to August 2021, and prior to that as President of Healthcare Informatics (HI) leading the development of ResMed's HI solutions and ResMed itself to its current standing as a global digital health leader, with an expanding portfolio of device- and SaaS-based offerings. He joined ResMed in 2012 through the acquisition of Umbian Inc. of which he was co-founder and President. Before ResMed and Umbian, Mr. Sodhi worked in the financial services industry, designing, developing and managing SaaS solutions. He was Senior Vice President of Business Development and Chief Technology Officer for Skipjack Financial Services from 2005 to 2009, and co-founder and Chief Technology Officer of TransActive Ecommerce Solutions from 2000 to 2005. Mr. Sodhi is on the board of directors of Forefront Dermatology, EyeCare Partners and NovaResp Technologies. Mr. Sodhi holds an MBA and a B.S. in Mathematics and Statistics from Dalhousie University in Halifax, Nova Scotia. - Rajwant Sodhi,在全球信息学、软件服务技术和电子商务业务解决方案方面拥有超过25年的经验,横跨医疗保健、金融和电信行业。此前,他曾于2017年7月至2021年8月担任ResMed软件即服务(SaaS)业务总裁,在此之前,他担任Healthcare Informatics(HI)总裁,领导ResMed HI解决方案的开发,并将ResMed提升至目前作为全球数字健康领导者的地位,拥有不断扩大的基于设备和SaaS的产品组合。他于2012年通过收购Umbian Inc.加入ResMed,他是该公司的联合创始人兼总裁。在ResMed和Umbian之前,Sodhi先生曾在金融服务行业工作,设计、开发和管理SaaS解决方案。他曾于2005年至2009年担任Skipjack Financial Services的业务发展高级副总裁兼首席技术官,并于2000年至2005年担任TransActive Ecommerce Solutions的联合创始人兼首席技术官。Sodhi先生是Forefront Dermatology、EyeCare Partners和NovaResp Technologies的董事会成员。Sodhi先生拥有新斯科舍省哈利法克斯Dalhousie大学的MBA和数学与统计学学士学位。
- Rajwant Sodhi,has more than 25 years of experience in global informatics, software service technology and ecommerce business solutions, across the healthcare, financial, and telecom industries. Previously he served as the President of ResMed's software as a service (SaaS) business from July 2017 to August 2021, and prior to that as President of Healthcare Informatics (HI) leading the development of ResMed's HI solutions and ResMed itself to its current standing as a global digital health leader, with an expanding portfolio of device- and SaaS-based offerings. He joined ResMed in 2012 through the acquisition of Umbian Inc. of which he was co-founder and President. Before ResMed and Umbian, Mr. Sodhi worked in the financial services industry, designing, developing and managing SaaS solutions. He was Senior Vice President of Business Development and Chief Technology Officer for Skipjack Financial Services from 2005 to 2009, and co-founder and Chief Technology Officer of TransActive Ecommerce Solutions from 2000 to 2005. Mr. Sodhi is on the board of directors of Forefront Dermatology, EyeCare Partners and NovaResp Technologies. Mr. Sodhi holds an MBA and a B.S. in Mathematics and Statistics from Dalhousie University in Halifax, Nova Scotia.
- Christopher Twomey
-
Christopher Twomey,自2018年7月起担任生命科学基因组分析仪器公司Bionano Genomics(BNGO)的董事和审计委员会主席。从1990年3月到2007年退休,Twomey先生曾在Biosite担任多个职务,最近担任财务高级副总裁和首席财务官。1981至1990年,Twomey先生任职于安永会计师事务所,担任审计经理。他在被收购之前曾担任Senomyx和凯斯制药等上市公司的董事和审计委员会主席。Twomey先生拥有加州大学圣巴巴拉分校商业经济学学士学位。
Christopher Twomey,has served as a director and chair of the audit committee of Bionano Genomics (Nasdaq: BNGO), a life sciences genome analysis instrumentation company since July 2018. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. He previously served as a director and chair of the audit committee for public companies, such as Senomyx and Cadence Pharmaceuticals, prior to their acquisitions. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara. - Christopher Twomey,自2018年7月起担任生命科学基因组分析仪器公司Bionano Genomics(BNGO)的董事和审计委员会主席。从1990年3月到2007年退休,Twomey先生曾在Biosite担任多个职务,最近担任财务高级副总裁和首席财务官。1981至1990年,Twomey先生任职于安永会计师事务所,担任审计经理。他在被收购之前曾担任Senomyx和凯斯制药等上市公司的董事和审计委员会主席。Twomey先生拥有加州大学圣巴巴拉分校商业经济学学士学位。
- Christopher Twomey,has served as a director and chair of the audit committee of Bionano Genomics (Nasdaq: BNGO), a life sciences genome analysis instrumentation company since July 2018. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. He previously served as a director and chair of the audit committee for public companies, such as Senomyx and Cadence Pharmaceuticals, prior to their acquisitions. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara.
- Sandra Beaver
-
Sandra Beaver,在全球拥有超过20年的战略和运营财务经验,涉足众多行业,包括医疗保健、医疗器械、游戏、企业技术和制造。Beaver女士是Lyra Health的首席财务官,该公司是一家领先的心理健康解决方案提供商,负责监督财务、会计、投资者关系、设施、采购和企业发展。在2025年6月担任这一职务之前,她曾在医美上市公司Evolus担任了三年的首席财务官。在加入Evolus之前,Beaver女士曾在全球数据和技术公司Experian和全球游戏公司IGT担任高级财务职务。Beaver女士拥有马萨诸塞大学工商管理学士学位和加州大学洛杉矶分校关系数据库设计专业称号。
Sandra Beaver,has more than 20 years of strategic and operational finance experience globally and across many industries including healthcare, medical devices, gaming, enterprise technology and manufacturing. Ms. Beaver is the CFO at Lyra Health, a leading provider of mental health solutions, overseeing finance, accounting, investor relations, facilities, procurement and corporate development. Before starting this role in June 2025, she served as CFO at Evolus, a publicly traded medical aesthetics company, for three years. Before Evolus, Ms. Beaver held senior finance positions at global data and technology company, Experian, and global gaming company, IGT. Ms. Beaver holds a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA. - Sandra Beaver,在全球拥有超过20年的战略和运营财务经验,涉足众多行业,包括医疗保健、医疗器械、游戏、企业技术和制造。Beaver女士是Lyra Health的首席财务官,该公司是一家领先的心理健康解决方案提供商,负责监督财务、会计、投资者关系、设施、采购和企业发展。在2025年6月担任这一职务之前,她曾在医美上市公司Evolus担任了三年的首席财务官。在加入Evolus之前,Beaver女士曾在全球数据和技术公司Experian和全球游戏公司IGT担任高级财务职务。Beaver女士拥有马萨诸塞大学工商管理学士学位和加州大学洛杉矶分校关系数据库设计专业称号。
- Sandra Beaver,has more than 20 years of strategic and operational finance experience globally and across many industries including healthcare, medical devices, gaming, enterprise technology and manufacturing. Ms. Beaver is the CFO at Lyra Health, a leading provider of mental health solutions, overseeing finance, accounting, investor relations, facilities, procurement and corporate development. Before starting this role in June 2025, she served as CFO at Evolus, a publicly traded medical aesthetics company, for three years. Before Evolus, Ms. Beaver held senior finance positions at global data and technology company, Experian, and global gaming company, IGT. Ms. Beaver holds a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.
- Christopher J. Twomey
-
Christopher J. Twomey,1990年3月,他加入Biosite Incorporated(医疗诊断公司)担任各种职务并不断被提拔,最后他担任高级副总裁负责财务和首席财务官直到2007年退休。在Biosite时,他负责财务、人力资源、设施和信息系统部门。从1981年到1990年,他在Ernst & Young LLP担任审计经理。2013年8月以来,他担任Tandem Diabetes Care, Inc.(医疗设备公司)的董事和审计委员会主席。他是Cadence Pharmaceuticals, Inc.(专业制药公司,2014年被Mallinckrodt plc收购)的前董事和审计委员会主席。他持有圣巴巴拉市的加州大学(University of California)的学士学位。
Christopher J. Twomey has served as a member of Board of Directors since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990 Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Since August 2013 Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company. Mr. Twomey is also a former director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey holds a B.A. from the University of California at Santa Barbara. - Christopher J. Twomey,1990年3月,他加入Biosite Incorporated(医疗诊断公司)担任各种职务并不断被提拔,最后他担任高级副总裁负责财务和首席财务官直到2007年退休。在Biosite时,他负责财务、人力资源、设施和信息系统部门。从1981年到1990年,他在Ernst & Young LLP担任审计经理。2013年8月以来,他担任Tandem Diabetes Care, Inc.(医疗设备公司)的董事和审计委员会主席。他是Cadence Pharmaceuticals, Inc.(专业制药公司,2014年被Mallinckrodt plc收购)的前董事和审计委员会主席。他持有圣巴巴拉市的加州大学(University of California)的学士学位。
- Christopher J. Twomey has served as a member of Board of Directors since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990 Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Since August 2013 Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company. Mr. Twomey is also a former director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey holds a B.A. from the University of California at Santa Barbara.
- John F. Sheridan
-
John F. Sheridan,从2012年3月至2013年2月,Sheridan先生曾担任Rapiscan Systems, Inc.的首席运营官,这是一个安全设备和系统的供应商。自2004年11月至2010年3月,Sheridan先生担任Volcano Corporation NASDAQ: VOLC的研发和运营部的执行副总裁,这是一个医疗技术公司。从2002年5月到2004年5月,Sheridan先生担任CardioNet, Inc.业务部的执行副总裁,这是一家医疗技术公司。从1998年5月到2002年5月,他担任Digirad公司运营部的副总裁,这是一家医疗成像公司。Sheridan先生持有West Florida大学化学学士学位和Boston大学工商管理硕士学位。
John F. Sheridan previously served as Executive Vice President and Chief Operating Officer since April 2013. Prior to joining company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004 Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. NASDAQ: BEAT. From March 1998 to May 2002 he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University. - John F. Sheridan,从2012年3月至2013年2月,Sheridan先生曾担任Rapiscan Systems, Inc.的首席运营官,这是一个安全设备和系统的供应商。自2004年11月至2010年3月,Sheridan先生担任Volcano Corporation NASDAQ: VOLC的研发和运营部的执行副总裁,这是一个医疗技术公司。从2002年5月到2004年5月,Sheridan先生担任CardioNet, Inc.业务部的执行副总裁,这是一家医疗技术公司。从1998年5月到2002年5月,他担任Digirad公司运营部的副总裁,这是一家医疗成像公司。Sheridan先生持有West Florida大学化学学士学位和Boston大学工商管理硕士学位。
- John F. Sheridan previously served as Executive Vice President and Chief Operating Officer since April 2013. Prior to joining company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004 Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. NASDAQ: BEAT. From March 1998 to May 2002 he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.
- Sandra Beaver
-
Sandra Beaver,自2022年9月起担任Evolus, Inc.首席财务官。从2019年10月到2022年9月,Beaver女士担任全球信息服务公司Experian的财务高级副总裁,负责该公司一半的北美B2B业务部门。从2002年11月到2019年9月,比弗女士担任的职务责任和范围越来越大,包括合并财务规划与分析副总裁,以及Game Technology PLC副总裁兼首席财务官。比弗女士拥有马萨诸塞大学阿默斯特分校伊森伯格管理学院的学士学位。
Sandra Beaver,has served as Evolus, Inc. Chief Financial Officer since September 2022. From October 2019 to September 2022, Mrs. Beaver served as Senior Vice President of Finance at Experian, a global information services company, where she was responsible for half of company's North America B2B business units. From November 2002 to September 2019, Mrs. Beaver held roles with increasing levels of responsibility and scope including Vice President of Consolidated Financial Planning & Analysis, and Vice President and Chief Financial Officer at Game Technology PLC. Mrs. Beaver holds a B.A. from the Isenberg School of Management at the University of Massachusetts Amherst. - Sandra Beaver,自2022年9月起担任Evolus, Inc.首席财务官。从2019年10月到2022年9月,Beaver女士担任全球信息服务公司Experian的财务高级副总裁,负责该公司一半的北美B2B业务部门。从2002年11月到2019年9月,比弗女士担任的职务责任和范围越来越大,包括合并财务规划与分析副总裁,以及Game Technology PLC副总裁兼首席财务官。比弗女士拥有马萨诸塞大学阿默斯特分校伊森伯格管理学院的学士学位。
- Sandra Beaver,has served as Evolus, Inc. Chief Financial Officer since September 2022. From October 2019 to September 2022, Mrs. Beaver served as Senior Vice President of Finance at Experian, a global information services company, where she was responsible for half of company's North America B2B business units. From November 2002 to September 2019, Mrs. Beaver held roles with increasing levels of responsibility and scope including Vice President of Consolidated Financial Planning & Analysis, and Vice President and Chief Financial Officer at Game Technology PLC. Mrs. Beaver holds a B.A. from the Isenberg School of Management at the University of Massachusetts Amherst.
高管简历
中英对照 |  中文 |  英文- Elizabeth A. Gasser
ElizabethA.Gasser自2020年1月起担任公司战略和企业发展执行Vice President。在加入我们公司之前,Gasser女士自2017年6月起担任独立顾问,为董事会和执行团队提供战略和企业发展解决方案。2016年1月至2017年6月,她担任高通技术公司(Qualcomm Technologies,Inc.)企业战略Vice President。QTI是高通公司(纳斯达克市场代码:QCOM)的子公司,QTI是移动设备和其他无线产品所用技术和产品的开发和商业化的全球领先企业。在此之前,从2012年11月到2016年1月,她是QTI战略发展的Vice President,在此之前,她从2006年开始担任其他与战略相关的职责递增的职务。Gasser女士拥有剑桥大学(University of Cambridge)经济学学士学位和硕士学位。
Elizabeth A. Gasser has served as our Executive Vice President of Strategy and Corporate Development since January 2020. Prior to joining our company, Ms. Gasser served from June 2017 as an independent adviser providing strategic and corporate development solutions to boards and executive teams. From January 2016 to June 2017 she was Vice President of Corporate Strategy at QUALCOMM Technologies, Inc. QTI, a subsidiary of QUALCOMM Incorporated (NASDAQ: QCOM), a global leader in the development and commercialization of technologies and products used in mobile devices and other wireless products. Prior to that, from November 2012 to January 2016 she was Vice President of Strategic Development at QTI, after serving in other strategic related roles of increasing responsibility beginning in 2006. Ms. Gasser holds a B.A. and an M.A. in Economics from the University of Cambridge.- ElizabethA.Gasser自2020年1月起担任公司战略和企业发展执行Vice President。在加入我们公司之前,Gasser女士自2017年6月起担任独立顾问,为董事会和执行团队提供战略和企业发展解决方案。2016年1月至2017年6月,她担任高通技术公司(Qualcomm Technologies,Inc.)企业战略Vice President。QTI是高通公司(纳斯达克市场代码:QCOM)的子公司,QTI是移动设备和其他无线产品所用技术和产品的开发和商业化的全球领先企业。在此之前,从2012年11月到2016年1月,她是QTI战略发展的Vice President,在此之前,她从2006年开始担任其他与战略相关的职责递增的职务。Gasser女士拥有剑桥大学(University of Cambridge)经济学学士学位和硕士学位。
- Elizabeth A. Gasser has served as our Executive Vice President of Strategy and Corporate Development since January 2020. Prior to joining our company, Ms. Gasser served from June 2017 as an independent adviser providing strategic and corporate development solutions to boards and executive teams. From January 2016 to June 2017 she was Vice President of Corporate Strategy at QUALCOMM Technologies, Inc. QTI, a subsidiary of QUALCOMM Incorporated (NASDAQ: QCOM), a global leader in the development and commercialization of technologies and products used in mobile devices and other wireless products. Prior to that, from November 2012 to January 2016 she was Vice President of Strategic Development at QTI, after serving in other strategic related roles of increasing responsibility beginning in 2006. Ms. Gasser holds a B.A. and an M.A. in Economics from the University of Cambridge.
- Leigh A. Vosseller
LeighA.Vosseller自2018年6月起担任我们的执行Vice President,首席财务官和财务主管,并于2018年1月至2018年5月担任高级副总裁,首席财务官和财务主管。Vosseller女士是我们的首席财务和会计官。她于2013年加入我们,担任财务Vice President,并于2017年8月晋升为财务高级副总裁。在此之前,她于2011年开始担任Genoptix的Vice President和首席财务官,2008年首次加入Genoptix。此前,她曾担任Biosite公司的高级财务职务,在那里她曾担任开发国际扩张的财务和行政基础设施的关键职务。Vosseller女士是一名不活跃的注册会计师,持有密苏里州立大学(Missouri State University)会计学学士学位。
Leigh A. Vosseller has served as our Executive Vice President, Chief Financial Officer, and Treasurer since June 2018 and served as Senior Vice President, Chief Financial Officer and Treasurer from January 2018 to May 2018. Ms. Vosseller is our principal financial and accounting officer. She joined us as Vice President of Finance in 2013 and was promoted to Senior Vice President of Finance in August 2017. Prior to that time, she served as Vice President and Chief Financial Officer at Genoptix, beginning in 2011 after initially joining Genoptix in 2008. Prior to that she held a senior finance position at Biosite where she played a key role in developing the financial and administrative infrastructure for international expansion. Ms. Vosseller is a certified public accountant inactive and holds a B.S. in Accounting from Missouri State University.- LeighA.Vosseller自2018年6月起担任我们的执行Vice President,首席财务官和财务主管,并于2018年1月至2018年5月担任高级副总裁,首席财务官和财务主管。Vosseller女士是我们的首席财务和会计官。她于2013年加入我们,担任财务Vice President,并于2017年8月晋升为财务高级副总裁。在此之前,她于2011年开始担任Genoptix的Vice President和首席财务官,2008年首次加入Genoptix。此前,她曾担任Biosite公司的高级财务职务,在那里她曾担任开发国际扩张的财务和行政基础设施的关键职务。Vosseller女士是一名不活跃的注册会计师,持有密苏里州立大学(Missouri State University)会计学学士学位。
- Leigh A. Vosseller has served as our Executive Vice President, Chief Financial Officer, and Treasurer since June 2018 and served as Senior Vice President, Chief Financial Officer and Treasurer from January 2018 to May 2018. Ms. Vosseller is our principal financial and accounting officer. She joined us as Vice President of Finance in 2013 and was promoted to Senior Vice President of Finance in August 2017. Prior to that time, she served as Vice President and Chief Financial Officer at Genoptix, beginning in 2011 after initially joining Genoptix in 2008. Prior to that she held a senior finance position at Biosite where she played a key role in developing the financial and administrative infrastructure for international expansion. Ms. Vosseller is a certified public accountant inactive and holds a B.S. in Accounting from Missouri State University.
- John Sheridan
John Sheridan,2012年3月至2013年2月担任安全设备和系统提供商Rapiscan Systems,Inc.的首席运营官。Sheridan先生于2004年11月至2010年3月期间担任医疗技术公司Volcano医疗器械的研发和运营执行副总裁。从2002年5月到2004年5月,Sheridan先生在医疗技术公司CardioNet公司担任运营执行副总裁,该公司现以BioTelemetry,Inc.(纳斯达克:BEAT)的名义运营。1998年3月至2002年5月,在医学影像公司Digirad Corporation担任运营副总裁。Sheridan先生此前曾于2021年3月至2025年4月期间担任Acutus Medical, Inc.(纳斯达克:AFIB)的董事。Sheridan先生拥有西佛罗里达大学化学学士学位和波士顿大学MBA学位。
John Sheridan,served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan previously served as a director of Acutus Medical, Inc. (Nasdaq: AFIB) from March 2021 to April 2025. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University.- John Sheridan,2012年3月至2013年2月担任安全设备和系统提供商Rapiscan Systems,Inc.的首席运营官。Sheridan先生于2004年11月至2010年3月期间担任医疗技术公司Volcano医疗器械的研发和运营执行副总裁。从2002年5月到2004年5月,Sheridan先生在医疗技术公司CardioNet公司担任运营执行副总裁,该公司现以BioTelemetry,Inc.(纳斯达克:BEAT)的名义运营。1998年3月至2002年5月,在医学影像公司Digirad Corporation担任运营副总裁。Sheridan先生此前曾于2021年3月至2025年4月期间担任Acutus Medical, Inc.(纳斯达克:AFIB)的董事。Sheridan先生拥有西佛罗里达大学化学学士学位和波士顿大学MBA学位。
- John Sheridan,served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan previously served as a director of Acutus Medical, Inc. (Nasdaq: AFIB) from March 2021 to April 2025. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University.
- Rick Carpenter
Rick Carpenter,自2020年2月起担任Inseego公司工程高级副总裁,领导全球工程团队,负责设备软硬件、云软件、质量保证、法规和产品认证以及技术账户管理。2017年4月至2020年1月,他在Capsule Technologies担任IoMT业务总经理和工程高级总监,该公司将医疗设备和可穿戴设备集成到一个安全的医疗级系统中,该系统收集数据并将其提供给医疗保健专业人员以供患者监测。在此之前,从2009年5月到2017年3月,Carpenter先生在史密斯微软件担任工程高级副总裁。在其职业生涯的早期,他曾在Nextwave Wireless、希拉无线、通用动力、摩托罗拉和电装担任过各种工程开发和领导职务。Carpenter先生拥有得克萨斯大学二叠纪盆地计算机科学学士学位,并完成了得克萨斯大学阿灵顿分校计算机科学硕士学位的课程作业。
Rick Carpenter,served from February 2020 as the Senior Vice President of Engineering at Inseego Corporation, where he led the worldwide engineering team and was responsible for device hardware and software, cloud software, quality assurance, regulatory and product certification and technical account management. From April 2017 to January 2020, he was the General Manager of the IoMT Business and the Senior Director of Engineering at Capsule Technologies, a company that integrates medical devices and wearables into a secure medical grade system that collects data and provides it to healthcare professionals for patient monitoring. Prior to that, from May 2009 until March 2017, Mr. Carpenter served as the Senior Vice President of Engineering at Smith Micro Software. Earlier in his career, he held various engineering development and leadership roles at Nextwave Wireless, Sierra Wireless, General Dynamics, Motorola and Denso. Mr. Carpenter holds a B.S. in Computer Science from The University of Texas Permian Basin, and completed coursework for an M.S. in Computer Science from The University of Texas at Arlington.- Rick Carpenter,自2020年2月起担任Inseego公司工程高级副总裁,领导全球工程团队,负责设备软硬件、云软件、质量保证、法规和产品认证以及技术账户管理。2017年4月至2020年1月,他在Capsule Technologies担任IoMT业务总经理和工程高级总监,该公司将医疗设备和可穿戴设备集成到一个安全的医疗级系统中,该系统收集数据并将其提供给医疗保健专业人员以供患者监测。在此之前,从2009年5月到2017年3月,Carpenter先生在史密斯微软件担任工程高级副总裁。在其职业生涯的早期,他曾在Nextwave Wireless、希拉无线、通用动力、摩托罗拉和电装担任过各种工程开发和领导职务。Carpenter先生拥有得克萨斯大学二叠纪盆地计算机科学学士学位,并完成了得克萨斯大学阿灵顿分校计算机科学硕士学位的课程作业。
- Rick Carpenter,served from February 2020 as the Senior Vice President of Engineering at Inseego Corporation, where he led the worldwide engineering team and was responsible for device hardware and software, cloud software, quality assurance, regulatory and product certification and technical account management. From April 2017 to January 2020, he was the General Manager of the IoMT Business and the Senior Director of Engineering at Capsule Technologies, a company that integrates medical devices and wearables into a secure medical grade system that collects data and provides it to healthcare professionals for patient monitoring. Prior to that, from May 2009 until March 2017, Mr. Carpenter served as the Senior Vice President of Engineering at Smith Micro Software. Earlier in his career, he held various engineering development and leadership roles at Nextwave Wireless, Sierra Wireless, General Dynamics, Motorola and Denso. Mr. Carpenter holds a B.S. in Computer Science from The University of Texas Permian Basin, and completed coursework for an M.S. in Computer Science from The University of Texas at Arlington.
- Shannon Hansen
Shannon Hansen于2022年1月加入公司,担任高级副总裁、总法律顾问、首席合规官和秘书,在其任职期间,她一直负责公司的法律、合规和隐私职能。在加入Tandem Diabetes Care, Inc.公司之前,Hansen女士于2020年4月至2021年9月期间担任Alto Pharmacy的总法律顾问、公司秘书和首席隐私官,负责监督法律、隐私和合规职能的发展。在加入奥拓药房之前,她曾于2009年5月至2020年2月在雅培担任过各种领导职务。2021年8月,Hansen女士开始担任PHC控股公司的独立外部审计和监事会成员。在她职业生涯的早期,她是Kirkland & Ellis LLP的合伙人、美国专利商标局的副律师和杜邦公司的工艺工程师。汉森女士拥有卡内基梅隆大学化学工程学士学位和斯坦福大学法学院法学博士学位。
Shannon Hansen,joined the Company as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary in January 2022 and throughout her tenure, she has maintained responsibility for the Company's legal, compliance and privacy functions. Before joining Tandem Diabetes Care, Inc. Company, Ms. Hansen served as General Counsel, Corporate Secretary and Chief Privacy Officer at Alto Pharmacy from April 2020 to September 2021, where she oversaw the development of the legal, privacy and compliance functions. Before her role at Alto Pharmacy, she held various leadership roles at Abbott Laboratories from May 2009 to February 2020. In August 2021, Ms. Hansen began serving as an Independent External Audit and Supervisory Board Member for PHC Holdings Corporation. Earlier in her career, she was a partner at Kirkland & Ellis LLP, an Associate Solicitor at the United States Patent and Trademark Office and a process engineer at DuPont. Ms. Hansen holds a B.S. in Chemical Engineering from Carnegie Mellon University, and a J.D. from Stanford Law School.- Shannon Hansen于2022年1月加入公司,担任高级副总裁、总法律顾问、首席合规官和秘书,在其任职期间,她一直负责公司的法律、合规和隐私职能。在加入Tandem Diabetes Care, Inc.公司之前,Hansen女士于2020年4月至2021年9月期间担任Alto Pharmacy的总法律顾问、公司秘书和首席隐私官,负责监督法律、隐私和合规职能的发展。在加入奥拓药房之前,她曾于2009年5月至2020年2月在雅培担任过各种领导职务。2021年8月,Hansen女士开始担任PHC控股公司的独立外部审计和监事会成员。在她职业生涯的早期,她是Kirkland & Ellis LLP的合伙人、美国专利商标局的副律师和杜邦公司的工艺工程师。汉森女士拥有卡内基梅隆大学化学工程学士学位和斯坦福大学法学院法学博士学位。
- Shannon Hansen,joined the Company as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary in January 2022 and throughout her tenure, she has maintained responsibility for the Company's legal, compliance and privacy functions. Before joining Tandem Diabetes Care, Inc. Company, Ms. Hansen served as General Counsel, Corporate Secretary and Chief Privacy Officer at Alto Pharmacy from April 2020 to September 2021, where she oversaw the development of the legal, privacy and compliance functions. Before her role at Alto Pharmacy, she held various leadership roles at Abbott Laboratories from May 2009 to February 2020. In August 2021, Ms. Hansen began serving as an Independent External Audit and Supervisory Board Member for PHC Holdings Corporation. Earlier in her career, she was a partner at Kirkland & Ellis LLP, an Associate Solicitor at the United States Patent and Trademark Office and a process engineer at DuPont. Ms. Hansen holds a B.S. in Chemical Engineering from Carnegie Mellon University, and a J.D. from Stanford Law School.
- Jean Claude Kyrillos
Jean Claude Kyrillos,于2020年2月至2023年6月在Envista Holdings担任运营公司总裁职务,最近担任诊断和数字解决方案总裁。在此之前,Kyrillos先生于2016年5月至2019年2月担任高通的医疗保健部门高通 Life的高级副总裁兼总经理。在任职高通之前,Kyrillos先生于2011年8月至2016年5月在Becton Dickinson担任高级副总裁兼输液解决方案总经理。在此之前,Kyrillos先生于2008年1月至2011年8月在ResMed Inc.担任领导职务,最近担任ResMed Ventures和Initiatives总裁。Kyrillos先生自2016年1月起担任圣地亚哥血库的独立董事会董事,并于2020年1月至2022年12月担任主席。Kyrillos先生获得了高露洁大学历史荣誉学士学位和哈佛商学院MBA学位。
Jean Claude Kyrillos,served in operating company president roles at Envista Holdings from February 2020 to June 2023, most recently as President of Diagnostics and Digital Solutions. Prior to that, Mr. Kyrillos was Senior Vice President and General Manager at Qualcomm Life, the healthcare division at Qualcomm, from May 2016 to February 2019. Before his time at Qualcomm, Mr. Kyrillos served as Senior Vice President and General Manager of infusion solutions at Becton Dickinson from August 2011 to May 2016. Prior to that, Mr. Kyrillos held leadership positions at ResMed Inc. from January 2008 to August 2011, most recently serving as President of ResMed Ventures and Initiatives. Mr. Kyrillos has served as an independent board director of San Diego Blood Bank since January 2016 and as Chair from January 2020 to December 2022. Mr. Kyrillos received a B.A. with Honors in History from Colgate University and an MBA from Harvard Business School.- Jean Claude Kyrillos,于2020年2月至2023年6月在Envista Holdings担任运营公司总裁职务,最近担任诊断和数字解决方案总裁。在此之前,Kyrillos先生于2016年5月至2019年2月担任高通的医疗保健部门高通 Life的高级副总裁兼总经理。在任职高通之前,Kyrillos先生于2011年8月至2016年5月在Becton Dickinson担任高级副总裁兼输液解决方案总经理。在此之前,Kyrillos先生于2008年1月至2011年8月在ResMed Inc.担任领导职务,最近担任ResMed Ventures和Initiatives总裁。Kyrillos先生自2016年1月起担任圣地亚哥血库的独立董事会董事,并于2020年1月至2022年12月担任主席。Kyrillos先生获得了高露洁大学历史荣誉学士学位和哈佛商学院MBA学位。
- Jean Claude Kyrillos,served in operating company president roles at Envista Holdings from February 2020 to June 2023, most recently as President of Diagnostics and Digital Solutions. Prior to that, Mr. Kyrillos was Senior Vice President and General Manager at Qualcomm Life, the healthcare division at Qualcomm, from May 2016 to February 2019. Before his time at Qualcomm, Mr. Kyrillos served as Senior Vice President and General Manager of infusion solutions at Becton Dickinson from August 2011 to May 2016. Prior to that, Mr. Kyrillos held leadership positions at ResMed Inc. from January 2008 to August 2011, most recently serving as President of ResMed Ventures and Initiatives. Mr. Kyrillos has served as an independent board director of San Diego Blood Bank since January 2016 and as Chair from January 2020 to December 2022. Mr. Kyrillos received a B.A. with Honors in History from Colgate University and an MBA from Harvard Business School.
- Mark Novara
Mark Novara,是一位在医疗器械、生命科学和制药行业拥有近25年一般管理、战略和营销经验的高管。在加入Tandem Diabetes Care, Inc.公司之前,他于2023年2月至2023年11月在麦肯锡公司担任医疗技术/生命科学实践高级顾问。在此之前,诺瓦拉先生在Becton Dickinson(BD)担任高管职务超过11年,最近一次是在2020年6月至2022年12月期间担任药物交付解决方案业务部门的全球副总裁/总经理。他还担任高级副总裁,负责BD两个部门的全球战略营销,2018年5月至2020年6月为医疗部门,2015年12月至2018年5月为生命科学部门。Novara先生还在2013年11月至2015年12月期间担任糖尿病护理业务部门的全球副总裁/总经理,并在2011年7月至2013年11月期间担任制药系统业务部门的战略营销和业务发展总监。他还曾在Hoffman-La Roche和赛诺菲-安万特担任领导职务。Novara先生拥有维拉诺瓦大学生物学学士学位和哥伦比亚大学医疗保健管理硕士学位。
Mark Novara,is an executive with nearly 25 years of general management, strategy and marketing experience in the medical device, life science and pharmaceutical industries. Before joining Tandem Diabetes Care, Inc. Company, he served as Senior Advisor in the Medical Technology/Life Science practice at McKinsey & Company from February 2023 to November 2023. Before that time, Mr. Novara held executive positions at Becton Dickinson (BD) for more than 11 years, most recently as a Worldwide Vice President/General Manager in the Medication Delivery Solutions business unit from June 2020 to December 2022. He also served as Senior Vice President, Global Strategic Marketing for two of BD's segments, Medical from May 2018 to June 2020, and Life Sciences from December 2015 to May 2018. Mr. Novara was also a Worldwide Vice President/General Manager in the Diabetes Care business unit from November 2013 to December 2015, and Director of Strategic Marketing and Business Development in the Pharmaceutical Systems business unit from July 2011 to November 2013. He also held leadership positions with Hoffman-La Roche and Sanofi-Aventis. Mr. Novara holds a B.S. in Biology from Villanova University and a Master's in Healthcare Management from Columbia University.- Mark Novara,是一位在医疗器械、生命科学和制药行业拥有近25年一般管理、战略和营销经验的高管。在加入Tandem Diabetes Care, Inc.公司之前,他于2023年2月至2023年11月在麦肯锡公司担任医疗技术/生命科学实践高级顾问。在此之前,诺瓦拉先生在Becton Dickinson(BD)担任高管职务超过11年,最近一次是在2020年6月至2022年12月期间担任药物交付解决方案业务部门的全球副总裁/总经理。他还担任高级副总裁,负责BD两个部门的全球战略营销,2018年5月至2020年6月为医疗部门,2015年12月至2018年5月为生命科学部门。Novara先生还在2013年11月至2015年12月期间担任糖尿病护理业务部门的全球副总裁/总经理,并在2011年7月至2013年11月期间担任制药系统业务部门的战略营销和业务发展总监。他还曾在Hoffman-La Roche和赛诺菲-安万特担任领导职务。Novara先生拥有维拉诺瓦大学生物学学士学位和哥伦比亚大学医疗保健管理硕士学位。
- Mark Novara,is an executive with nearly 25 years of general management, strategy and marketing experience in the medical device, life science and pharmaceutical industries. Before joining Tandem Diabetes Care, Inc. Company, he served as Senior Advisor in the Medical Technology/Life Science practice at McKinsey & Company from February 2023 to November 2023. Before that time, Mr. Novara held executive positions at Becton Dickinson (BD) for more than 11 years, most recently as a Worldwide Vice President/General Manager in the Medication Delivery Solutions business unit from June 2020 to December 2022. He also served as Senior Vice President, Global Strategic Marketing for two of BD's segments, Medical from May 2018 to June 2020, and Life Sciences from December 2015 to May 2018. Mr. Novara was also a Worldwide Vice President/General Manager in the Diabetes Care business unit from November 2013 to December 2015, and Director of Strategic Marketing and Business Development in the Pharmaceutical Systems business unit from July 2011 to November 2013. He also held leadership positions with Hoffman-La Roche and Sanofi-Aventis. Mr. Novara holds a B.S. in Biology from Villanova University and a Master's in Healthcare Management from Columbia University.
- Leigh Vosseller
Leigh Vosseller,自2018年6月起担任Tandem Diabetes Care, Inc.执行副总裁、首席财务官、财务主管,并于2018年1月至2018年5月担任高级副总裁、首席财务官和财务主管。Vosseller女士是糖尿病保健公司的首席财务和会计官。她于2013年加入糖尿病保健,担任财务副总裁,2017年8月晋升为财务高级副总裁。在此之前,她于2011年开始在Genoptix担任副总裁兼首席财务官,此前她最初于2008年加入Genoptix。在此之前,她在诊断公司Biosite担任高级财务职位,在那里她在发展国际扩张的金融和行政基础设施方面发挥了关键作用。自2021年1月以来,Vosseller女士担任圣地亚哥女孩公司财务委员会的董事和主席,该公司是一家非营利组织,为社区中服务不足的女孩提供以STEM为重点、以研究为基础的方案。Vosseller女士是一名注册会计师(非在职),拥有密苏里州立大学会计学学士学位。
Leigh Vosseller,has served as Tandem Diabetes Care, Inc. Executive Vice President, Chief Financial Officer, and Treasurer since June 2018, and served as Senior Vice President, Chief Financial Officer and Treasurer from January 2018 to May 2018. Ms. Vosseller is Tandem Diabetes Care, Inc. principal financial and accounting officer. She joined Tandem Diabetes Care, Inc. as Vice President of Finance in 2013 and was promoted to Senior Vice President of Finance in August 2017. Before that time, she served as Vice President and Chief Financial Officer at Genoptix, beginning in 2011, after initially joining Genoptix in 2008. Before that she held a senior finance position at Biosite, a diagnostics company, where she played a key role in developing the financial and administrative infrastructure for international expansion. Since January 2021, Ms. Vosseller has served as a director and chair of the finance committee of Girls Inc. of San Diego, a non-profit organization that provides STEM-focused, research-based programming to underserved girls in the community. Ms. Vosseller is a certified public accountant (inactive) and holds a B.S. in Accounting from Missouri State University.- Leigh Vosseller,自2018年6月起担任Tandem Diabetes Care, Inc.执行副总裁、首席财务官、财务主管,并于2018年1月至2018年5月担任高级副总裁、首席财务官和财务主管。Vosseller女士是糖尿病保健公司的首席财务和会计官。她于2013年加入糖尿病保健,担任财务副总裁,2017年8月晋升为财务高级副总裁。在此之前,她于2011年开始在Genoptix担任副总裁兼首席财务官,此前她最初于2008年加入Genoptix。在此之前,她在诊断公司Biosite担任高级财务职位,在那里她在发展国际扩张的金融和行政基础设施方面发挥了关键作用。自2021年1月以来,Vosseller女士担任圣地亚哥女孩公司财务委员会的董事和主席,该公司是一家非营利组织,为社区中服务不足的女孩提供以STEM为重点、以研究为基础的方案。Vosseller女士是一名注册会计师(非在职),拥有密苏里州立大学会计学学士学位。
- Leigh Vosseller,has served as Tandem Diabetes Care, Inc. Executive Vice President, Chief Financial Officer, and Treasurer since June 2018, and served as Senior Vice President, Chief Financial Officer and Treasurer from January 2018 to May 2018. Ms. Vosseller is Tandem Diabetes Care, Inc. principal financial and accounting officer. She joined Tandem Diabetes Care, Inc. as Vice President of Finance in 2013 and was promoted to Senior Vice President of Finance in August 2017. Before that time, she served as Vice President and Chief Financial Officer at Genoptix, beginning in 2011, after initially joining Genoptix in 2008. Before that she held a senior finance position at Biosite, a diagnostics company, where she played a key role in developing the financial and administrative infrastructure for international expansion. Since January 2021, Ms. Vosseller has served as a director and chair of the finance committee of Girls Inc. of San Diego, a non-profit organization that provides STEM-focused, research-based programming to underserved girls in the community. Ms. Vosseller is a certified public accountant (inactive) and holds a B.S. in Accounting from Missouri State University.
- Rick Carpenter
Rick Carpenter,他于2009年5月加入公司,担任公司的连通性和安全业务单元的工程副总裁,目前担任工程高级副总裁。加入Smith Micro公司之前,他曾担任NextWave Wireless公司的工程副总裁 ,在那里他负责WiMAX芯片开发。从2000年到2005年,他担任AirPrime公司(最终被Sierra Wireless公司收购)的CDMA产品软件开发总监。他也担任Motorola公司和DENSO Wireless公司的工程管理职务,并于1986年5月开始他的职业生涯。他持有德克萨斯大学二叠纪盆地分校(The University of Texas of the Permian Basin)的计算机科学学士学位,以及德克萨斯大学阿灵顿分校(University of Texas at Arlington)的计算机科学与工程硕士学位。
Rick Carpenter joined the Company in May 2009 as the Vice President, Engineering for the Company’s Connectivity & Security Business Unit and then served as the Vice President and General Manager of the Wireless Business Unit. Mr. Carpenter currently serves as the Senior Vice President of Engineering. Prior to joining Smith Micro, Mr. Carpenter served as a Vice President of Engineering at NextWave Wireless where he was responsible for WiMAX chipset development. From 2000 to 2005 he was Director of Software Engineering for CDMA products at AirPrime, which was ultimately acquired by Sierra Wireless. Mr. Carpenter has also held engineering management positions at Motorola and DENSO Wireless and started his professional career in May of 1986. He holds a BS in Computer Science from the University of Texas, Permian Basin and studied Masters-level Computer Science & Engineering at the University of Texas Arlington.- Rick Carpenter,他于2009年5月加入公司,担任公司的连通性和安全业务单元的工程副总裁,目前担任工程高级副总裁。加入Smith Micro公司之前,他曾担任NextWave Wireless公司的工程副总裁 ,在那里他负责WiMAX芯片开发。从2000年到2005年,他担任AirPrime公司(最终被Sierra Wireless公司收购)的CDMA产品软件开发总监。他也担任Motorola公司和DENSO Wireless公司的工程管理职务,并于1986年5月开始他的职业生涯。他持有德克萨斯大学二叠纪盆地分校(The University of Texas of the Permian Basin)的计算机科学学士学位,以及德克萨斯大学阿灵顿分校(University of Texas at Arlington)的计算机科学与工程硕士学位。
- Rick Carpenter joined the Company in May 2009 as the Vice President, Engineering for the Company’s Connectivity & Security Business Unit and then served as the Vice President and General Manager of the Wireless Business Unit. Mr. Carpenter currently serves as the Senior Vice President of Engineering. Prior to joining Smith Micro, Mr. Carpenter served as a Vice President of Engineering at NextWave Wireless where he was responsible for WiMAX chipset development. From 2000 to 2005 he was Director of Software Engineering for CDMA products at AirPrime, which was ultimately acquired by Sierra Wireless. Mr. Carpenter has also held engineering management positions at Motorola and DENSO Wireless and started his professional career in May of 1986. He holds a BS in Computer Science from the University of Texas, Permian Basin and studied Masters-level Computer Science & Engineering at the University of Texas Arlington.
- John F. Sheridan
John F. Sheridan,从2012年3月至2013年2月,Sheridan先生曾担任Rapiscan Systems, Inc.的首席运营官,这是一个安全设备和系统的供应商。自2004年11月至2010年3月,Sheridan先生担任Volcano Corporation NASDAQ: VOLC的研发和运营部的执行副总裁,这是一个医疗技术公司。从2002年5月到2004年5月,Sheridan先生担任CardioNet, Inc.业务部的执行副总裁,这是一家医疗技术公司。从1998年5月到2002年5月,他担任Digirad公司运营部的副总裁,这是一家医疗成像公司。Sheridan先生持有West Florida大学化学学士学位和Boston大学工商管理硕士学位。
John F. Sheridan previously served as Executive Vice President and Chief Operating Officer since April 2013. Prior to joining company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004 Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. NASDAQ: BEAT. From March 1998 to May 2002 he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.- John F. Sheridan,从2012年3月至2013年2月,Sheridan先生曾担任Rapiscan Systems, Inc.的首席运营官,这是一个安全设备和系统的供应商。自2004年11月至2010年3月,Sheridan先生担任Volcano Corporation NASDAQ: VOLC的研发和运营部的执行副总裁,这是一个医疗技术公司。从2002年5月到2004年5月,Sheridan先生担任CardioNet, Inc.业务部的执行副总裁,这是一家医疗技术公司。从1998年5月到2002年5月,他担任Digirad公司运营部的副总裁,这是一家医疗成像公司。Sheridan先生持有West Florida大学化学学士学位和Boston大学工商管理硕士学位。
- John F. Sheridan previously served as Executive Vice President and Chief Operating Officer since April 2013. Prior to joining company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004 Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. NASDAQ: BEAT. From March 1998 to May 2002 he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.
- Susan M. Morrison
Susan M. Morrison,自2013年9月起一直担任首席行政官。从2013年4月到2013年9月,她担任人力资源部、企业和投资者关系部的副总裁。从2009年1月至2013年3月,Morrison女士担任企业和投资者关系部的总监;从2007年11月到2008年12月,担任企业服务部的总监。从2003年8月到2007年11月,Morrison女士在Biosite公司的企业与投资者关系方面担任不同的职位。Morrison女士拥有西密歇根大学(Western Michigan University)公共关系学士学位。
Susan M. Morrison has served as Chief Administrative Officer since September 2013 and as an Executive Vice President since December 2017. From April 2013 until September 2013 she served as Vice President, Human Resources, Corporate and Investor Relations. Ms. Morrison served as Director, Corporate and Investor Relations, from January 2009 to March 2013 and was Director, Corporate Services from November 2007 to December 2008. Prior to joining company, Ms. Morrison held various positions in Corporate and Investor Relations at Biosite from August 2003 through November 2007. Ms. Morrison holds a B.A. in Public Relations from Western Michigan University.- Susan M. Morrison,自2013年9月起一直担任首席行政官。从2013年4月到2013年9月,她担任人力资源部、企业和投资者关系部的副总裁。从2009年1月至2013年3月,Morrison女士担任企业和投资者关系部的总监;从2007年11月到2008年12月,担任企业服务部的总监。从2003年8月到2007年11月,Morrison女士在Biosite公司的企业与投资者关系方面担任不同的职位。Morrison女士拥有西密歇根大学(Western Michigan University)公共关系学士学位。
- Susan M. Morrison has served as Chief Administrative Officer since September 2013 and as an Executive Vice President since December 2017. From April 2013 until September 2013 she served as Vice President, Human Resources, Corporate and Investor Relations. Ms. Morrison served as Director, Corporate and Investor Relations, from January 2009 to March 2013 and was Director, Corporate Services from November 2007 to December 2008. Prior to joining company, Ms. Morrison held various positions in Corporate and Investor Relations at Biosite from August 2003 through November 2007. Ms. Morrison holds a B.A. in Public Relations from Western Michigan University.